A meta-analysis of the impact of monensin in lactating dairy cattle. Part 3. Health and reproduction.
A meta-analysis of the impact of monensin on health and reproductive outcomes in dairy cattle was conducted. A total of 16 papers were identified with sufficient data and quality to evaluate health and reproductive outcomes for monensin. The available trials provided approximately 9,500 cows with sufficient data for analysis. This provided good statistical power to examine the effects of monensin on health and reproduction. Over all the trials analyzed, monensin decreased the risk of ketosis [relative risk (RR) = 0.75], displaced abomasums (RR = 0.75), and mastitis (RR = 0.91). No significant effects of monensin were found for milk fever, lameness, dystocia, retained placenta, or metritis. Monensin had no effect on first-service conception risk (RR = 0.97) or days to pregnancy (hazard ratio = 0.93). However, the impact of monensin on dystocia, retained placenta, and metritis was heterogeneous for all 3 outcome measures and random effect models were utilized. Causes of the heterogeneity were explored with meta-regression. Days of treatment with monensin before calving increased the risk of dystocia. Delivery method of monensin influenced the incidence of retained placenta and metritis, with risk being lower with controlled release capsule treatment compared with delivery in either topdress or in a total mixed ration. Days of treatment before calving also influenced retained placenta with an increase in risk with more days treated before calving. Improvements in ketosis, displaced abomasums, and mastitis with monensin were achieved. Exposure to prolonged treatment in the dry period with monensin may increase the risk of dystocia and retained placenta.
Duffield
T F
TF
Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada N1G 2W1. tduffiel@uoguelph.ca
Rabiee
A R
AR
Lean
I J
IJ
D000827:Animal Welfare; D000818:Animals; D002417:Cattle / Q000502:physiology*; D002418:Cattle Diseases / Q000517:prevention & control*; D005260:Female; D006304:Health Status; D007476:Ionophores / Q000009:adverse effects / Q000494:pharmacology; D007774:Lactation / Q000187:drug effects* / Q000502:physiology; D008985:Monensin / Q000009:adverse effects / Q000494:pharmacology*; D012098:Reproduction / Q000187:drug effects* / Q000502:physiology
D007476:Ionophores; D008985:Monensin